1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Casdin Capital, LLC Buys MyoKardia Inc, Sarepta Therapeutics Inc, Blueprint Medicines Corp, Sells Loxo Oncology Inc, iShares Nasdaq Biotechnology Index Fund, Agios Pharmaceuticals Inc

Investment company Casdin Capital, LLC buys MyoKardia Inc, Sarepta Therapeutics Inc, Blueprint Medicines Corp, Sage Therapeutics Inc, Alnylam Pharmaceuticals Inc, Gritstone Oncology Inc, Gilead Sciences Inc, sells Loxo Oncology Inc, iShares Nasdaq Biotechnology Index Fund, Agios Pharmaceuticals Inc, Quotient, Neon Therapeutics Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Casdin Capital, LLC. As of 2019Q1, Casdin Capital, LLC owns 28 stocks with a total value of $904 million. These are the details of the buys and sells.

For the details of Casdin Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/casdin+capital%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Casdin Capital, LLC
  1. Spark Therapeutics Inc (ONCE) - 940,000 shares, 11.84% of the total portfolio. Shares added by 11.90%
  2. Blueprint Medicines Corp (BPMC) - 848,648 shares, 7.51% of the total portfolio. Shares added by 32.60%
  3. MyoKardia Inc (MYOK) - 1,285,000 shares, 7.39% of the total portfolio. Shares added by 62.66%
  4. Sage Therapeutics Inc (SAGE) - 400,000 shares, 7.04% of the total portfolio. Shares added by 28.21%
  5. bluebird bio Inc (BLUE) - 357,500 shares, 6.22% of the total portfolio. Shares added by 8.33%
New Purchase: Gilead Sciences Inc (GILD)

Casdin Capital, LLC initiated holding in Gilead Sciences Inc. The purchase prices were between $62.53 and $70.05, with an estimated average price of $66.46. The stock is now traded at around $65.30. The impact to a portfolio due to this purchase was 0.58%. The holding were 80,000 shares as of .

Added: MyoKardia Inc (MYOK)

Casdin Capital, LLC added to a holding in MyoKardia Inc by 62.66%. The purchase prices were between $39.23 and $55.82, with an estimated average price of $46.05. The stock is now traded at around $47.52. The impact to a portfolio due to this purchase was 2.85%. The holding were 1,285,000 shares as of .

Added: Sarepta Therapeutics Inc (SRPT)

Casdin Capital, LLC added to a holding in Sarepta Therapeutics Inc by 103.33%. The purchase prices were between $106.67 and $151.68, with an estimated average price of $128.32. The stock is now traded at around $119.19. The impact to a portfolio due to this purchase was 2.04%. The holding were 305,000 shares as of .

Added: Blueprint Medicines Corp (BPMC)

Casdin Capital, LLC added to a holding in Blueprint Medicines Corp by 32.60%. The purchase prices were between $48.7 and $86.6, with an estimated average price of $73.56. The stock is now traded at around $77.20. The impact to a portfolio due to this purchase was 1.85%. The holding were 848,648 shares as of .

Added: Sage Therapeutics Inc (SAGE)

Casdin Capital, LLC added to a holding in Sage Therapeutics Inc by 28.21%. The purchase prices were between $89.33 and $163.65, with an estimated average price of $144.22. The stock is now traded at around $167.05. The impact to a portfolio due to this purchase was 1.55%. The holding were 400,000 shares as of .

Added: Alnylam Pharmaceuticals Inc (ALNY)

Casdin Capital, LLC added to a holding in Alnylam Pharmaceuticals Inc by 25.35%. The purchase prices were between $72.76 and $93.45, with an estimated average price of $83.46. The stock is now traded at around $68.07. The impact to a portfolio due to this purchase was 0.93%. The holding were 445,000 shares as of .

Added: Gritstone Oncology Inc (GRTS)

Casdin Capital, LLC added to a holding in Gritstone Oncology Inc by 55.51%. The purchase prices were between $9.97 and $18.96, with an estimated average price of $13.4. The stock is now traded at around $11.04. The impact to a portfolio due to this purchase was 0.59%. The holding were 1,120,586 shares as of .

Sold Out: Loxo Oncology Inc (LOXO)

Casdin Capital, LLC sold out a holding in Loxo Oncology Inc. The sale prices were between $131.02 and $234.75, with an estimated average price of $222.49.

Sold Out: iShares Nasdaq Biotechnology Index Fund (IBB)

Casdin Capital, LLC sold out a holding in iShares Nasdaq Biotechnology Index Fund. The sale prices were between $96.43 and $115.11, with an estimated average price of $109.52.

Sold Out: Quotient Ltd (QTNT)

Casdin Capital, LLC sold out a holding in Quotient Ltd. The sale prices were between $6 and $11.07, with an estimated average price of $8.75.

Sold Out: Neon Therapeutics Inc (NTGN)

Casdin Capital, LLC sold out a holding in Neon Therapeutics Inc. The sale prices were between $4.24 and $6.46, with an estimated average price of $5.22.



Here is the complete portfolio of Casdin Capital, LLC. Also check out:

1. Casdin Capital, LLC's Undervalued Stocks
2. Casdin Capital, LLC's Top Growth Companies, and
3. Casdin Capital, LLC's High Yield stocks
4. Stocks that Casdin Capital, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)